Bull Case

Phase 2 clinical progress and clean safety signals in OK-101 or related ophthalmic assets could re-rate the pipeline versus small-cap eye-disease peers with earlier-stage programs.

A partnering or licensing transaction could fund development and reduce dilution, improving runway and execution visibility relative to cash-constrained biotech peers.

Positive trial readouts could expand addressable indications and support higher probability of approval, lifting expected revenue optionality versus peers still pre-proof-of-concept.

Improved capital access and milestone receipts could lower financing pressure, allowing more efficient R&D spend than peers forced into repeated equity raises.

Base Case

Clinical development advances slowly but remains capital intensive, so OKYO likely preserves pipeline optionality while trailing better-funded ophthalmic peers on speed and breadth.

Limited near-term revenue and negative operating margins keep valuation driven by trial milestones rather than fundamentals, similar to other early-stage biotech peers.

Periodic equity financing likely remains necessary to extend runway, which dilutes holders and constrains operating flexibility versus partnered or revenue-generating peers.

The most probable outcome is incremental data generation without a transformative partnership, leaving OKYO positioned as a speculative development-stage peer rather than a de-risked platform.

Bear Case

Clinical setbacks or inconclusive efficacy data could materially reduce program value, leaving OKYO behind peers that have already validated their mechanisms.

A weak cash position combined with negative interest coverage and limited operating cash generation could force dilutive financing on unfavorable terms.

If development timelines slip, the company may need to cut spending or reprioritize assets, shrinking competitive relevance versus better-capitalized ophthalmology peers.

Absent positive catalysts, the market could continue to assign a distressed optionality value, reflecting higher financing risk than peers with clearer clinical or commercial paths.

Overall Score

OKYO’s forward path is dominated by binary clinical and financing outcomes, leaving meaningful upside from successful data but a still-material dilution and execution burden versus peers.